Catalyst Event
Takeda Pharmaceutical Co Ltd (TAK) · Earnings Release
From KEDI Global Longevity Bio Index (KGLB)
5/13/2026, 12:00:00 AM
Full-year financial results for fiscal year 2025 are scheduled for May 13, 2026. This annual earnings release is estimated to have a medium price impact of at least 5% based on historical volatility and is expected.
Korean Translation
2025 회계연도 전체 재무 결과 발표가 2026년 5월 13일 예정됨. 연간 실적 발표는 과거 변동성을 바탕으로 5% 이상의 중간 수준 주가 영향이 예상됨.
Related Recent Events
Takeda Pharmaceutical Co Ltd (TAK) · Other
Current President & CEO Christophe Weber is scheduled to retire and will be succeeded by CEO-elect Julie Kim on June 24, 2026. This leadership change is estimated to have a high price impact of at least 10% due to potential shifts in corporate strategy and is expected.
6/24/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
U.S. FDA decision on the supplemental application for LEQEMBI IQLIK on 2026-05-24; price impact is estimated to be ≥10% as a major drug catalyst, expected.
5/24/2026, 12:00:00 AM
Medpace Holdings Inc (MEDP) · Other
Annual Meeting of Stockholders on May 15, 2026. Annual meetings usually have minor impact on stock price, estimated at >1%, scheduled.
5/15/2026, 12:00:00 AM
Viatris Inc (VTRS) · Earnings Release
Viatris is scheduled to report its first quarter 2026 financial results on May 7, 2026, with a webcast for investors scheduled. Earnings releases typically result in 5% or more price impact, so a Medium impact is expected.
5/7/2026, 12:00:00 AM
RELX PLC (RELX) · Other
The ex-dividend date for the proposed final dividend of 48.0 pence per share for the 2025 financial year is May 7, 2026. The payment date is June 18, 2026. Low importance is estimated based on typical dividend yield impact, scheduled.
5/7/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
Novo Nordisk is scheduled to release its Q1 2026 earnings report before the market opens on May 6, 2026, with high importance estimated due to potential 10% price impact, expected.
5/6/2026, 12:00:00 AM